Evidence map›Paper›PMID 41067863›Full record

GuidelineJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.

Steven P Rowe, Brian M Shuch, Mark W Ball, Axel Bex, Mehrbod S Javadi, Alan Klitzke, Karolien Goffin, Peter Mulders, Neeta Pandit-Taskar, Ashwin Singh Parihar and 3 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A prospective head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Trial
  2. Review
  3. Occult metastases detection and impact on management in renal cell carcinoma imaged with [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Steven P RoweDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas; steven.rowe@utsouthwestern.edu.
Brian M ShuchDepartment of Urology, University of California, Los Angeles, California.
Mark W BallUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Axel BexDepartment of Urology, Royal Free Hospital, London, United Kingdom, and The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mehrbod S JavadiBay Imaging Consultants Medical Group, Inc., Walnut Creek, California.
Alan KlitzkeDivision of Nuclear Medicine and Theranostics, Department of Diagnostic Imaging, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Karolien GoffinNuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Peter MuldersDepartment of Urology, Radboud University, Nijmegen, The Netherlands.
Neeta Pandit-TaskarDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ashwin Singh PariharDivision of Nuclear Medicine, Mallinckrodt Institute of Radiology, and Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Benjamin L VigliantiDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, Michigan.
Michael A GorinMilton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York; and.
Ken HerrmannDepartment of Nuclear Medicine, Universitätsklinikum Essen, Essen, Germany.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Anatomic imaging of renal masses provides limited information on the histology or likely aggressiveness of the tumor, leading to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrectomy. Molecular imaging can assist in risk stratification of indeterminate renal masses, potentially contributing to optimal patient decision-making. Two primary approaches have been explored for renal mass molecular imaging. The first is the use of agents that target carbonic anhydrase IX (CAIX), a cell-surface protein that is over-expressed on clear cell renal cell carcinoma (ccRCC) and generally not expressed on other renal tumors. A recent phase III trial (ZIRCON) is widely believed to have laid the groundwork for United States Food and Drug Administration approval of the CAIX monoclonal antibody

Indexed as

Kidney NeoplasmsMolecular ImagingNuclear MedicineCarcinoma, Renal CellHumansSocieties, Medicalgirentuximabmolecular imagingrenal massrenal tumorrisk stratificationsestamibi

Identifiers

PMID41067863
PMCPMC12676646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.